Jackson Creek Investment Advisors LLC Acquires New Shares in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Jackson Creek Investment Advisors LLC acquired a new stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 26,426 shares of the biopharmaceutical company's stock, valued at approximately $1,263,000.

Several other institutional investors also recently made changes to their positions in the stock. Farther Finance Advisors LLC boosted its holdings in Halozyme Therapeutics by 173.6% in the third quarter. Farther Finance Advisors LLC now owns 1,620 shares of the biopharmaceutical company's stock valued at $93,000 after acquiring an additional 1,028 shares during the last quarter. Janney Montgomery Scott LLC lifted its stake in shares of Halozyme Therapeutics by 38.4% in the 3rd quarter. Janney Montgomery Scott LLC now owns 36,020 shares of the biopharmaceutical company's stock valued at $2,062,000 after purchasing an additional 9,995 shares in the last quarter. QRG Capital Management Inc. purchased a new stake in shares of Halozyme Therapeutics during the 3rd quarter worth about $245,000. Foster & Motley Inc. acquired a new stake in Halozyme Therapeutics during the 3rd quarter worth approximately $609,000. Finally, Portside Wealth Group LLC raised its holdings in Halozyme Therapeutics by 132.1% in the third quarter. Portside Wealth Group LLC now owns 9,123 shares of the biopharmaceutical company's stock valued at $522,000 after buying an additional 5,192 shares during the period. 97.79% of the stock is owned by hedge funds and other institutional investors.

Halozyme Therapeutics Stock Up 0.0 %

Shares of NASDAQ:HALO traded up $0.01 during trading on Tuesday, hitting $61.45. The company's stock had a trading volume of 1,218,115 shares, compared to its average volume of 1,310,544. The company has a market capitalization of $7.57 billion, a PE ratio of 17.92, a PEG ratio of 0.42 and a beta of 1.32. Halozyme Therapeutics, Inc. has a fifty-two week low of $37.73 and a fifty-two week high of $65.53. The company has a debt-to-equity ratio of 4.14, a quick ratio of 9.15 and a current ratio of 7.80. The stock's 50-day moving average price is $55.96 and its two-hundred day moving average price is $54.68.

Remove Ads

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last announced its earnings results on Tuesday, February 18th. The biopharmaceutical company reported $1.19 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.17 by $0.02. The company had revenue of $298.01 million for the quarter, compared to analyst estimates of $285.74 million. Halozyme Therapeutics had a return on equity of 157.78% and a net margin of 43.74%. As a group, sell-side analysts expect that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current year.

Insider Activity

In other Halozyme Therapeutics news, SVP Michael J. Labarre sold 1,697 shares of the business's stock in a transaction on Thursday, February 27th. The shares were sold at an average price of $58.28, for a total transaction of $98,901.16. Following the completion of the sale, the senior vice president now owns 173,756 shares in the company, valued at $10,126,499.68. The trade was a 0.97 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Jeffrey William Henderson sold 10,000 shares of the stock in a transaction on Monday, January 6th. The stock was sold at an average price of $50.01, for a total transaction of $500,100.00. Following the sale, the director now directly owns 43,611 shares in the company, valued at $2,180,986.11. This trade represents a 18.65 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 31,697 shares of company stock worth $1,754,451. 2.40% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on HALO shares. HC Wainwright reiterated a "buy" rating on shares of Halozyme Therapeutics in a research note on Thursday, March 6th. Piper Sandler upped their price target on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the stock a "neutral" rating in a research report on Friday, January 10th. Wells Fargo & Company cut their price objective on Halozyme Therapeutics from $62.00 to $57.00 and set an "equal weight" rating on the stock in a research report on Monday, January 13th. Finally, Benchmark reaffirmed a "buy" rating and issued a $75.00 target price on shares of Halozyme Therapeutics in a research report on Thursday, February 20th. Four research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $62.78.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.